BACKGROUND/AIMS: Helicobacter pylori eradication rates achieved by first-line triple treatment with proton pump inhibitor (PPI), clarithromycin, and amoxicillin have decreased to 70~85%, in part due to increasing antimicrobial resistance. This study evaluated the trend in H. pylori eradication rates during the most recent 8 years in Daegu, Korea and analyzed different clinical factors between success group and failure group of H. pylori eradication. MATERIALS AND METHODS: This was a retrospective study at a single institution. A total of 768 H. pylori-positive patients who received one or two weeks of first-line triple regimens were included between January 2007 and October 2014. RESULTS: The overall H. pylori eradication rate was 86%. The eradication rate from years 2007 to 2014 was 80.5%, 89.4%, 95.6%, 85.5%, 87.9%, 75.8%, 83.3%, and 85.8%, respectively (P=0.027). There was no significant difference in the eradication rate among various PPIs (P=0.358). In addition, there were no significant difference of clinical factors between success and failure group of H. pylori eradication. CONCLUSIONS: The eradication rates of first-line triple therapy for H. pylori over 8 years were 75.8~95.6%. No significant difference in clinical factors were noted between success and failure group of H. pylori eradication. Triple therapy may be a useful regimen for H. pylori eradication in Daegu.
Amoxicillin ; Clarithromycin ; Daegu* ; Disease Eradication ; Helicobacter pylori* ; Helicobacter* ; Humans ; Korea ; Proton Pumps ; Retrospective Studies

BACKGROUND/AIMS: Failure of Helicobacter pylori eradication has increased over the past decade and is related to increased antibiotic resistance. The aim of this study was to estimate the eradication rates of H. pylori infection over the past 9 years in a single center. MATERIALS AND METHODS: From 2004 to 2013, a total of 5,715 patients were diagnosed with H. pylori infection and were prescribed first line triple regimens. 2,482 patients underwent tests for assessment of eradication by 13C-urea breath test, rapid urease test or histopathological examinations. RESULTS: The overall eradication rate of first line triple regimen was 80.4% and continually decreased during the study period (P=0.011). Among the triple regimens, the eradication rate of two-week and one-week regimens were 90.1% and 79.3%, each. The two-week regimen was superior to the one-week regimen (P=0.000). The overall eradication rates of second line quadruple regimen was 91.4% and there was no significant decrease in the annual eradication rates (P=0.708). The overall eradication rates of both first line and second line therapy were 81.9% and decreased gradually during the study period (P=0.011). Multivariate analysis revealed sex, age, type of proton pump inhibitor, and duration of eradication to be associated with eradication failure. CONCLUSIONS: The eradication rates of first line triple regimen has decreased gradually; however, the eradication rates of second line regimen remains unchanged. Triple regimens of two-weeks seem to be better than one.
Breath Tests ; Disease Eradication ; Drug Resistance, Microbial ; Helicobacter pylori* ; Humans ; Incheon ; Multivariate Analysis ; Proton Pumps ; Urease

BACKGROUND/AIMS: Eradication of Helicobacter pylori infection with standard triple therapy (TT) has declined primarily because of increased antibiotic resistance. Sequential therapy (ST) has been suggested as an alternative to TT for the first-line treatment of H. pylori. The purpose of this study was to compare the efficacy of ST with TT. METHODS: This was a multicenter, randomized open-label trial performed at nine centers in Korea. Patients with H. pylori infection were randomly assigned to receive either 7 day TT or 10 day ST. Eradication rates, drug compliance, and adverse events were compared among the two regimens. RESULTS: A total of 601 patients were enrolled between March 2011 and September 2014. The intention-to-treat eradication rates were 70.8% for TT and 82.4% for ST (p=0.001). The corresponding per protocol eradication rates were 76.9% and 88.8% for TT and ST, respectively (p=0.000). There were no statistically significant differences between the two regimens with respect to drug compliance and adverse events. CONCLUSIONS: ST achieved better eradication rates than TT as a first-line therapy for H. pylori eradication in Korea.
Compliance ; Disease Eradication ; Drug Resistance ; Drug Resistance, Microbial ; Helicobacter pylori* ; Helicobacter* ; Humans ; Korea*

BACKGROUND/AIMS: The eradication rate of Helicobacter pylori with standard triple therapy as a first-line treatment has decreased to 70~85%. Recently, concomitant therapy has been reported to overcome this decrease in eradication rate to some degree. The aim of this retrospective study was to compare the efficacy of 7-day concomitant therapy with that of 7-day standard triple therapy as a first-line treatment. MATERIALS AND METHODS: Between March 2013 and February 2017, the medical records of 261 patients who received 7-day standard triple therapy or 7-day concomitant therapy as a first-line H. pylori eradication therapy were retrospectively evaluated. Successful eradication was confirmed using the 13C-urea breath test 6 to 8 weeks after the end of the eradication therapy. RESULTS: This study included 261 patients, 140 patients in the standard triple therapy group and 121 in the concomitant therapy group. The H. pylori eradication rate by intention-to-treat analysis was 60.0% in the standard triple therapy group and 81.0% in the concomitant therapy group (P<0.001). In the per-protocol analysis, the H. pylori eradication rates in the standard triple therapy and concomitant therapy groups were 69.4% and 88.3%, respectively (P<0.001). CONCLUSIONS: Concomitant therapy was more effective as a first-line H. pylori eradication therapy than the standard triple therapy.
Breath Tests ; Disease Eradication ; Helicobacter pylori ; Helicobacter ; Humans ; Medical Records ; Retrospective Studies

On February 2022, WHO released the evidence-based guideline on control and elimination of human schistosomiasis, with aims to guide the elimination of schistosomiasis as a public health problem in disease-endemic countries by 2030 and promote the interruption of schistosomiasis transmission across the world. Based on the One Health concept, six evidence-based recommendations were proposed in this guideline. This article aims to analyze the feasibility of key aspects of this guideline in Chinese national schistosomiasis control program and illustrate the significance to guide the future actions for Chinese national schistosomiasis control program. Currently, the One Health concept has been embodied in the Chinese national schistosomiasis control program. Based on this new WHO guideline, the following recommendations are proposed for the national schistosomiasis control program of China: (1) improving the systematic framework building, facilitating the agreement of the cross-sectoral consensus, and building a high-level leadership group; (2) optimizing the current human and livestock treatments in the national schistosomiasis control program of China; (3) developing highly sensitive and specific diagnostics and the framework for verifying elimination of schistosomiasis; (4) accelerating the progress towards elimination of schistosomiasis and other parasitic diseases through integrating the national control programs for other parasitic diseases.
China/epidemiology* ; Disease Eradication ; Humans ; Public Health ; Schistosomiasis/prevention & control* ; World Health Organization

Schistosomiasis is a parasitic disease that seriously hinders socioeconomic developments and threatens public health security. To achieve the global elimination of schistosomiasis as a public health problem by 2030, WHO released the guideline on control and elimination of human schistosomiasis on February, 2022, with aims to provide evidence-based recommendations for schistosomiasis morbidity control, elimination of schistosomiasis as a public health problem, and ultimate interruption of schistosomiasis transmission in disease-endemic countries. Following concerted efforts for decades, great achievements have been obtained for schistosomiasis control in China where the disease was historically highly prevalent, and the country is moving towards schistosomiasis elimination. This article reviews the successful experiences from the national schistosmiasis control program in China, and summarizes their contributions to the formulation and implementation of the WHO guideline on control and elimination of human schistosomiasis. With the progress of the "Belt and Road" initiative, the world is looking forward to more China's solutions on schistosomiasis control.
China/epidemiology* ; Disease Eradication ; Humans ; Public Health ; Schistosomiasis/prevention & control* ; World Health Organization

BACKGROUND/AIMS: This nationwide, multicenter prospective randomized controlled trial aimed to compare the efficacy and safety of 10-day concomitant therapy (CT) and 10-day sequential therapy (ST) with 7-day clarithromycin-containing triple therapy (TT) as first-line treatment for Helicobacter pylori infection in the Korean population. METHODS: Patients with H. pylori infection were assigned randomly to 7d-TT (lansoprazole 30 mg, amoxicillin 1 g, and clarithromycin 500 mg twice daily for 7 days), 10d-ST (lansoprazole 30 mg and amoxicillin 1 g twice daily for the first 5 days, followed by lansoprazole 30 mg, clarithromycin 500 mg, and metronidazole 500 mg twice daily for the remaining 5 days), or 10d-CT (lansoprazole 30 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg twice daily for 10 days). The primary endpoint was eradication rate by intention-to-treat (ITT) and per-protocol (PP) analyses. RESULTS: A total of 1,141 patients were included. The 10d-CT protocol achieved a markedly higher eradication rate than the 7d-TT protocol in both the ITT (81.2% vs 63.9%) and PP analyses (90.6% vs 71.4%). The eradication rate of the 10d-ST protocol was superior to that of the 7d-TT protocol (76.3% vs 63.9%, ITT analysis; 85.0% vs 71.4%, PP analysis). No significant differences in adherence or serious side effects were found among the three treatment arms. CONCLUSIONS: The 10d-CT and 10d-ST regimens were superior to the 7d-TT regimen as standard first-line treatment in Korea.
Amoxicillin ; Arm ; Clarithromycin ; Disease Eradication ; Helicobacter pylori ; Helicobacter ; Humans ; Korea ; Lansoprazole ; Metronidazole ; Prospective Studies

Antimalarials ; therapeutic use ; Disease Eradication ; economics ; Humans ; Malaria ; diagnosis ; drug therapy ; prevention & control

Communicable Disease Control ; methods ; trends ; Disease Eradication ; organization & administration ; Hepatitis, Viral, Human ; epidemiology ; prevention & control ; Humans ; Public Health ; Singapore ; epidemiology

BACKGROUND/AIMS: The eradication rate of Helicobacter pylori (H. pylori) has been decreasing recently in Korea due to antibiotics resistance. The aim of this study was to investigate the trend of eradication rate and clinical factors affecting the eradication rate of H. pylori in the last 10 years in west Gyeonggi-do, Korea. METHODS: The trends of eradication rate of H. pylori, gender, age, concomitant mediations, and clinical factors were retrospectively evaluated in patients with H. pylori infection between 2006 and 2015 (n=2,485). RESULTS: The overall H. pylori eradication rate for the standard triple therapy was 82.5%. The annual eradication rates from 2006 to 2015 were 90%, 77.9%, 75.8%, 83.2%, 85.6%, 90.1%, 81.3%, 81.1%, 78.7%, and 78.8%, respectively, showing a significant decrement during the last five years (p < 0.001). Higher eradication rate was observed in males than in females (p < 0.001). Esomeprazole showed a higher eradication rate compared with pantoprazole between 2006 and 2010 (p < 0.022). Age and the use of probiotics and mucosal protective agents played no significant role in the H. pylori eradication rate. The overall eradication rate for bismuth-based quadruple therapy was 94.4%. CONCLUSIONS: The eradication rate of H. pylori over the last 10 years for first-line therapy ranged from 75.8 to 90.1%; the eradication rate for triple therapy has declined. However, the eradication rate for quadruple therapy has remained unchanged over the last 10 years.
Anti-Bacterial Agents ; Disease Eradication ; Esomeprazole ; Female ; Gyeonggi-do* ; Helicobacter pylori* ; Helicobacter* ; Humans ; Korea* ; Male ; Probiotics ; Protective Agents ; Retrospective Studies